Immunohistochemical Expression of Telomerase in Patients with Non-Small Cell Lung Cancer: Prediction of Metastasis and Prognostic Significance


ARAS G., KANMAZ D., Urer N., Purisa S., KADAKAL F., Yenturk E., ...More

ANTICANCER RESEARCH, vol.33, no.6, pp.2643-2650, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 6
  • Publication Date: 2013
  • Journal Name: ANTICANCER RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2643-2650
  • Istanbul University Affiliated: Yes

Abstract

Aim: To detect telomerase reverse transcriptase (TERT) expression in tissue and metastatic and non-metastatic lymph node samples from patients with non-small cell lung cancer; to evaluate whether TERT expression is correlated with pathological and clinical features, and/or patient survival times; to determine differences between TERT expression in metastatic and non-metastatic lymph nodes. Patients and Methods: Tumor tissue samples from 17 patients with squamous cell lung cancer and 11 patients with adenocarcinoma diagnosed between 2003 and 2004 were included in this study. All patients were diagnosed at our hospital and had samples stored in the pathology archive. Additionally, dissected lymph node samples, with and without metastases, were studied. Telomerase Gene Tex, Inc, Irvine, CA USA (TERT (2C4) antibody), Universal Kit (Lab Vision, Newmarket, UK) were used for immunohistochemical staining. Statistical analyses were performed using SPSS 17.0 statistical software. Results: TERT was positive in 18/28 of the samples, regardless of the histological tumor type. There was no significant correlation between TERT expression in lymph nodes with metastasis and clinical stage, histological type, tumor differentiation, or survival time. Conclusion: TERT expression may be used as a target for therapy. It may also be helpful in predicting metastasis but not in predicting survival time.